Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 14,141 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

NCT04730050
View directory record Official record
Conditions
Healthy
Interventions
TT-01025-CL
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 1 Interventional

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825
View directory record Official record
Conditions
Hypercholesterolemia, Heterozygous Familial
Interventions
mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
20
States / cities
Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 9, 2026, 5:55 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

NCT04984876
View directory record Official record
Conditions
Allergy, Peanut
Interventions
ligelizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 55 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional

Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter

NCT06257576
View directory record Official record
Conditions
Postoperative Urinary Tract Infection
Interventions
Tamsulosin, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
50 Years and older · Male only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years to 55 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Terminated Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

NCT01923389
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, 100 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain

NCT01256450
View directory record Official record
Conditions
Pain, Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 2 Interventional

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
AR1001, Placebo
Drug
Lead sponsor
AriBio Co., Ltd.
Industry
Eligibility
55 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Banning, California • Sacramento, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Nov 9, 2026, 5:55 AM EST
Recruiting Phase 3 Interventional

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

NCT01614457
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Nov 9, 2026, 5:55 AM EST
Recruiting Phase 2 Interventional

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

NCT07830719
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
YMI024, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Fairhope, Alabama • Foley, Alabama • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 2 Interventional

EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

NCT05480228
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
NRD135SE.1, Placebo
Drug · Other
Lead sponsor
James P. Rathmell, MD
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
San Diego, California • Clermont, Florida • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

NCT03291470
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of SRX251 Capsules in Healthy Female Volunteers

NCT00461370
View directory record Official record
Conditions
Healthy
Interventions
SRX251
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 3 Interventional

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

NCT00612170
View directory record Official record
Conditions
Fibromyalgia
Interventions
[S,S]-Reboxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
136
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 9, 2026, 5:55 AM EST
Terminated Phase 2Phase 3 Interventional Results available

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

NCT01878786
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
Drug
Lead sponsor
Matthew Cooper
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 2 Interventional Results available

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

NCT05865886
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
BI 1291583, Placebo to BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Denver, Colorado • Altamonte Springs, Florida • South Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

NCT04750902
View directory record Official record
Conditions
Dental Caries
Interventions
0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
10 Years to 14 Years
Enrollment
2,025 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
8
States / cities
Loma Linda, California • Gainesville, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 9, 2026, 5:55 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

NCT02047656
View directory record Official record
Conditions
Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions
LFF269, Placebo to LFF269
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 1 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

NCT01686256
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 9, 2026, 5:55 AM EST
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Nov 9, 2026, 5:55 AM EST
Recruiting Not applicable Interventional

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

NCT05758545
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
COMS One device, Sham device
Device
Lead sponsor
Piomic Medical
Industry
Eligibility
22 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Castro Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 9, 2026, 5:55 AM EST